An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Tapentadol (Primary) ; Morphine
- Indications Pain
- Focus Therapeutic Use
- Sponsors Grunenthal
- 28 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Nov 2018.
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.